Non-colorectal GI tumors
Enhance diagnosis with advanced genetic analysis
Our next-generation sequencing assay for noncolorectal GI cancer assists in diagnosis, including variations in the most commonly mutated PDGFRA and KIT genes, along with NF1, BRAF, and other RAS genes. The test also includes detection of SETD2 and TP53 mutations, which have been shown to take on an aggressive clinical course.
Non-colorectal GI tumors Test menu
Non-colorectal GI tumors
Key testing
Advantages
- Included genes are carefully selected for their association with GIST.
- Confirms diagnosis of GIST in patients who have unusual lesions in the GI tract.
- Pinpoints genetic mutation to inform treatment and prognosis.
Highlights
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.